Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4771261 in Healthy Participants and ADPKD
NCT06734234Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, randomised, double-blind trial of GSK4771261 in autosomal dominant polycystic kidney disease (ADPKD) (15 arms), sponsored by GSK. Primary endpoints: Number of Participants with Adverse Events at Day 182, Number of Participants with Serious Adverse Events at Day 182 and 4 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
GSK4771261
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06734234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06734234.